Compare PLUG & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLUG | BLLN |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 1999 | N/A |
| Metric | PLUG | BLLN |
|---|---|---|
| Price | $2.32 | $80.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $2.09 | ★ $129.57 |
| AVG Volume (30 Days) | ★ 79.4M | 318.7K |
| Earning Date | 03-02-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,919,000.00 | N/A |
| Revenue This Year | $32.17 | $45.89 |
| Revenue Next Year | $14.99 | $30.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.90 | N/A |
| 52 Week Low | $0.69 | $61.96 |
| 52 Week High | $4.58 | $138.70 |
| Indicator | PLUG | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 54.69 |
| Support Level | $2.12 | $63.98 |
| Resistance Level | $2.54 | $86.01 |
| Average True Range (ATR) | 0.17 | 5.61 |
| MACD | 0.02 | 1.30 |
| Stochastic Oscillator | 58.89 | 75.47 |
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.